July 30, 2014 | The developer of the universal flu vaccine BiondVax announced that it has completed studies which validate the effectiveness of a vaccine against the deadly H7 avian flu virus. The H7 avian flu strain is highly contagious, infecting 76 percent of people and killing 33 percent on average. Studies were recently released confirming the viability of BiondVax’s M-001 vaccine, the universal flu vaccine, against two strains of avian flu, H5 and H7. In line with Food & Drug Administration standards in the United States, BiondVax’s M-001 vaccine doubled the chances of adequate protection against contracting H7 in mice studies. BiondVax, a publicly traded company, has a team of 14 scientists devoted to developing their breakthroughs in vaccination at its headquarters in the Weizmann Institute of Science Park in Nes Tziona, Israel.